Cargando…

Interleukin‐6/signal transducer and activator of transcription 3 promotes prostate cancer resistance to androgen deprivation therapy via regulating pituitary tumor transforming gene 1 expression

Prostate cancer can progress from androgen dependence to androgen deprivation resistance with some unknown mechanisms. The current study aims to explore the possible role of pituitary tumor transforming gene1 (PTTG1) in castration‐resistant prostate cancer (CRPC). Initially, we found that PTTG1 expr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Shengquan, Liu, Qian, Liao, Qianjin, Wu, Qingjian, Sun, Bishao, Yang, Zhenxing, Hu, Xiaoyan, Tan, Mingjia, Li, Longkun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834804/ https://www.ncbi.nlm.nih.gov/pubmed/29288516 http://dx.doi.org/10.1111/cas.13493

Ejemplares similares

Increased Piezo1 channel activity in interstitial Cajal-like cells induces bladder hyperactivity by functionally interacting with NCX1 in rats with cyclophosphamide-induced cystitis
por: Liu, Qian, et al.
Publicado: (2018)

Transcription Factors Involved in Prostate Gland Adaptation to Androgen Deprivation
por: Rosa-Ribeiro, Rafaela, et al.
Publicado: (2014)

Zinc levels in seminal plasma and their correlation with male infertility: A systematic review and meta-analysis
por: Zhao, Jiang, et al.
Publicado: (2016)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions
por: Decker, Keith F., et al.
Publicado: (2012)

PDE1A polymorphism contributes to the susceptibility of nephrolithiasis
por: Yang, Zhenxing, et al.
Publicado: (2017)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Supposed pituitary-production of human chorionic Gonadotropin induced by androgen deprivation therapy
por: Yoshimura, Koji, et al.
Publicado: (2019)

Medication utilization evaluation of androgen deprivation therapy for prostate cancer in Taiwan
por: Liao, Kuang-Ming, et al.
Publicado: (2020)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Reply: Prostate cancer, insulin and androgen deprivation therapy
por: Lehrer, S
Publicado: (2003)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
por: Corona, Giovanni, et al.
Publicado: (2021)

Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
por: Bassey, Iya Eze, et al.
Publicado: (2020)

Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer
por: Ishizaki, Fumio, et al.
Publicado: (2013)

Androgen Deprivation-Induced Senescence Promotes Outgrowth of Androgen-Refractory Prostate Cancer Cells
por: Burton, Dominick G. A., et al.
Publicado: (2013)

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
por: Hwang, Justin H., et al.
Publicado: (2019)

Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells
por: LIU, TIANCHENG, et al.
Publicado: (2012)

Identification of the Transcription Factor Relationships Associated with Androgen Deprivation Therapy Response and Metastatic Progression in Prostate Cancer
por: Sharma, Nitya V., et al.
Publicado: (2018)

Androgen Deprivation Induces Transcriptional Reprogramming in Prostate Cancer Cells to Develop Stem Cell-Like Characteristics
por: Verma, Shiv, et al.
Publicado: (2020)

An Update on the Changing Indications for Androgen Deprivation Therapy for Prostate Cancer
por: Myklak, Kristene, et al.
Publicado: (2011)

The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer
por: Shaw, Greg L., et al.
Publicado: (2016)

Androgen deprivation therapy as backbone therapy in the management of prostate cancer
por: Merseburger, Axel S, et al.
Publicado: (2016)

Metabolomic effects of androgen deprivation therapy treatment for prostate cancer
por: Chi, Jen‐Tsan, et al.
Publicado: (2020)

Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders
por: Liu, Jui-Ming, et al.
Publicado: (2020)

Relugolix – The novel oral androgen deprivation therapy for prostate cancer
por: Jena, Rahul
Publicado: (2020)

Biomarkers of Response to Neoadjuvant Androgen Deprivation in Localised Prostate Cancer
por: Pechlivanis, Maree, et al.
Publicado: (2021)

Immunosuppressive environment in response to androgen deprivation treatment in prostate cancer
por: Qin, Caipeng, et al.
Publicado: (2022)

Risk of ischemic stroke in patients with prostate cancer receiving androgen deprivation therapy in Taiwan
por: Liao, Kuang-Ming, et al.
Publicado: (2019)

Cyclophosphamide-induced HCN1 channel upregulation in interstitial Cajal-like cells leads to bladder hyperactivity in mice
por: Liu, Qian, et al.
Publicado: (2017)

Interplay of Epidermal Growth Factor Receptor and Signal Transducer and Activator of Transcription 3 in Prostate Cancer: Beyond Androgen Receptor Transactivation
por: Lin, Shian-Ren, et al.
Publicado: (2021)

Erratum: Comparative study of serum zinc concentrations in benign and malignant prostate disease: A Systematic Review and Meta-Analysis
por: Zhao, Jiang, et al.
Publicado: (2016)

Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel
por: Jiménez, Natalia, et al.
Publicado: (2022)

Hypothalamic-Pituitary-Thyroid Axis Set Point Alterations Are Associated With Body Composition in Androgen-Deprived Men
por: Hoermann, Rudolf, et al.
Publicado: (2017)

Androgen deprivation therapy for prostate cancer: indications, contraindications and possible consequences
por: Karl, Alexander, et al.
Publicado: (2009)

Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
por: Røe, Kathrine, et al.
Publicado: (2012)

Prostate Carcinogenesis with Diabetes and Androgen-Deprivation-Therapy-Related Diabetes: An Update
por: Hara, Noboru
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_3rba2nf44dqqc2lj47bk17dvqi